Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577135 · ClinicalTrials.gov registry record · Phase 3
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
NCT00577135 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 308 participants.
The verdict
NCT00577135, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
Study Summary
Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid accumulation in various organs and limbs. Diuretics are often used to address the problem of fluid accumulation, but the optimal dose and the amount of time over which to administer each dose are unclear. This study will compare high and low doses of diuretics administered over longer and shorter periods of time to determine the safest and most effective combination.
Interventions
- DRUG Furosemide-Q12 hour bolus
- DRUG Furosemide-Continuous Infusion
- DRUG Furosemide-Low Intensification
- DRUG Furosemide-High Intensification
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577135
The ClinicalTrials.gov registry entry for NCT00577135 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Furosemide-Q12 hour bolus is the first listed.
NCT00577135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577135 about?
NCT00577135 is a clinical study titled "Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)". Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid accumulation in various organs and limbs. Diuretics are often used to addr...
What is the current status of trial NCT00577135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2008-02. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00577135?
The interventions under investigation include: Furosemide-Q12 hour bolus (DRUG), Furosemide-Continuous Infusion (DRUG), Furosemide-Low Intensification (DRUG), Furosemide-High Intensification (DRUG).
Who is sponsoring clinical trial NCT00577135?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.